HCPCS Level II · Medical services and quality measures
M1428Patients who have bilateral absence of eyes any time during the patient's history through the end of the measurement period
✓ Active
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About M1428
M1428 is an HCPCS Level II code in the M series (medical services and quality measures), describing patients who have bilateral absence of eyes any time during the patient's history through the end of the measurement period.
It was added to HCPCS effective 01/01/2026.
Its Medicare coverage code is "C", meaning coverage is left to the Medicare contractor's judgment.
Details
- Short description
- Bilateral absence of eyes
- Date added
- 01/01/2026
- Action effective
- 01/01/2026
- BETOS
- Z2
Related M14xx codes
- M1400Patients who died during the follow-up period
- M1401Stages i-iii breast cancer
- M1402Patients receiving an initial chemotherapy regimen with a defined duration with the eligible clinician or group
- M1403Patients with baseline and follow-up promis surveys documented in the medical record
- M1404Patients on a therapeutic clinical trial
- M1405Patients with recurrence/disease progression
- M1406Patients who leave the practice during the follow-up period
- M1407Patients who died during the follow-up period
- M1408Patients who have germline brca testing completed before diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer
- M1409Patients who received germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis
- M1410Patients who did not have germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis
- M1411Currently on first-line immune checkpoint inhibitors without chemotherapy
Common questions about M1428
Is HCPCS M1428 still valid?
- Yes. M1428 is active in the CMS October 2026 HCPCS file.
Does Medicare cover M1428?
- Its coverage code is "C": coverage is left to the Medicare contractor's judgment. Check the local coverage determination for your region.